MIT’s Recursive Language Models rethink AI memory by treating documents like searchable environments, enabling models to ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

研究人员提出的递归语言模型（Recursive Language Models, RLMs）通过引入Python交互环境，让模型学会写代码去分块读取、检索并递归调用自身处理信息，成功在千万级Token的超长文本任务中实现了性能与成本的双重突破。

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

2025年的最后一天， MIT CSAIL提交了一份具有分量的工作。当整个业界都在疯狂卷模型上下文窗口（Context ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

从宏观数据来看，名校学历的经济回报依然显著。根据教育部与智联招聘联合发布的《2024中国高校毕业生就业趋势报告》，985/211院校毕业生的平均起薪仍比普通院校高出35%至50%，进入头部企业的比例高达42%，是后者的2.3倍。这些数字似乎印证了学历 ...

Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...